Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.

Abstract

In the past decade, accumulating evidence highlighted the role of monoamine oxidases (MAOs) in cardiovascular disease (CVD). MAOs are flavoenzymes located in the outer mitochondrial membrane, responsible for the degradation of neurotransmitters and biogenic amines. During this process they generate hydrogen peroxide, aldehydes and ammonia, species that can target mitochondria and induce mitochondrial dysfunction and cardiomyocyte death. Indeed, MAO inhibition affords cardioprotection in several models of CVD, such as ischemia/reperfusion, heart failure and diabetes. Importantly, a few studies provided encouraging results suggesting that MAO inhibition might be beneficial also in patients with CVD. Thus, selective and reversible MAO inhibitors, currently used as therapy for depression and neurodegenerative disorders, might be considered as candidate drugs for the treatment of CVD.

• Authors: Soni Deshwal, Moises Di Sante, Fabio Di Lisa, Nina Kaludercic
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 33 Pg. 64-69 (04 2017) ISSN: 1471-4973 [Electronic] England
• PMID: 28528298 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Monoamine Oxidase Inhibitors
• Monoamine Oxidase

Topics

• Animals
• Cardiovascular Diseases (drug therapy, metabolism)
• Humans
• Mitochondria (drug effects, metabolism)
• Monoamine Oxidase (metabolism)
• Monoamine Oxidase Inhibitors (pharmacology, therapeutic use)
• Myocytes, Cardiac (drug effects, metabolism)